MELK is an Oncogenic Kinase Essential for Mitotic Progression in Basal-Like Breast Cancer Cells
Yubao Wang,Young-Mi Lee,Lukas Baitsch,Alan Huang,Yi Xiang,Haoxuan Tong,Ana Lako,Thanh Von,Christine Choi,Elgene Lim,Junxia Min,Li,Frank Stegmeier,Robert Schlegel,Michael J. Eck,Nathanael S. Gray,Timothy J. Mitchison,Jean J. Zhao
DOI: https://doi.org/10.7554/elife.01763
IF: 7.7
2018-01-01
eLife
Abstract:Despite marked advances in breast cancer therapy, basal-like breast cancer (BBC), an aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains difficult to treat. In this study, we report the identification of MELK as a novel oncogenic kinase from an in vivo tumorigenesis screen using a kinome-wide open reading frames (ORFs) library. Analysis of clinical data reveals a high level of MELK overexpression in BBC, a feature that is largely dependent on FoxM1, a master mitotic transcription factor that is also found to be highly overexpressed in BBC. Ablation of MELK selectively impairs proliferation of basal-like, but not luminal breast cancer cells both in vitro and in vivo. Mechanistically, depletion of MELK in BBC cells induces caspase-dependent cell death, preceded by defective mitosis. Finally, we find that Melk is not required for mouse development and physiology. Together, these data indicate that MELK is a normally non-essential kinase, but is critical for BBC and thus represents a promising selective therapeutic target for the most aggressive subtype of breast cancer. DOI: http://dx.doi.org/10.7554/eLife.01763.001